- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 473/32 - Atome d'azote
Détention brevets de la classe C07D 473/32
Brevets de cette classe: 249
Historique des publications depuis 10 ans
|
15
|
16
|
15
|
15
|
9
|
22
|
11
|
19
|
10
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Signal Pharmaceuticals, LLC | 181 |
20 |
| Boehringer Ingelheim International GmbH | 4640 |
8 |
| Celgene Corporation | 1396 |
8 |
| Chengdu Baiyu Pharmaceutical Co., Ltd. | 68 |
6 |
| Board of Regents, The University of Texas System | 5869 |
5 |
| Takeda Pharmaceutical Company Limited | 2710 |
5 |
| CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 193 |
5 |
| Neupharma, Inc. | 72 |
5 |
| S*BIO Pte Ltd. | 24 |
5 |
| AstraZeneca AB | 2886 |
4 |
| Cancer Research Technology Limited | 529 |
4 |
| Incyte Holdings Corporation | 665 |
4 |
| Research Triangle Institute | 404 |
4 |
| Kangbaida (Sichuan) Biotechnology Co., Ltd. | 23 |
4 |
| F. Hoffmann-La Roche AG | 7948 |
3 |
| The Regents of the University of California | 20108 |
3 |
| Wyeth LLC | 655 |
3 |
| Purdue Research Foundation | 3673 |
3 |
| Ildong Pharmaceutical Co., Ltd. | 91 |
3 |
| Incyte Corporation | 1025 |
3 |
| Autres propriétaires | 144 |